5 results about "Cinacalcet" patented technology

The invention discloses a preparation method of cinacalcet hydrochloride. The preparation method comprises the following steps: 1) carrying out a reaction on 3-(3-trifluoromethylphenyl) propanol and phosphorus oxychloride; first post-treatment: extracting the product obtained in the step 1) by using an organic solvent, drying and concentrating to obtain 1-(3-chloropropyl)-3-trifluoromethyl benzene; (2) carrying out substitution reaction on the 1-(3-chloropropyl)-3-trifluoromethyl benzene obtained by the first post-treatment and (R)-1-(1-naphthyl) ethylamine; the product obtained in the second step is subjected to extraction, drying and concentration through an organic solvent and then subjected to a salt forming reaction with hydrochloric acid, and cinacalcet hydrochloride is obtained.According to the method, it is guaranteed that the product has the good yield and high purity, meanwhile, the impurity content, especially oxidation impurities, is remarkably reduced, and the appearance color and luster of cinacalcet hydrochloride are effectively improved.

The invention discloses a preparation method of cilnipride tartrate, which is characterized in that YT2303S-01 is used as a starting material, an intermediate 1 and an intermediate 2 are prepared in sequence, and finally the preparation of the cilnipride tartrate is completed. The raw materials adopted by the invention are commercially available products, the raw material sources are stable, and large-scale and industrial production can be conveniently carried out.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

The present invention relates to a particle size reduction process using inert gas for preparation of nitrosamine free Cinacalcet salt. Wherein, Cinacalcet salt is substantially free of nitrosamine impurities.

The invention provides application of cinacalcet and pharmaceutically acceptable salts thereof in preparation of antifungal drugs, discovers that the clinically marketed drug cinacalcet has a new antifungal application, realizes effective redevelopment of existing drugs, expands treatment indications of the drugs, and provides a new technical path and a potential chemical entity for drug reutilization. Experimental results show that cinacalcet has a good inhibition effect on various pathogenic fungi and has certain broad-spectrum antifungal activity. As the medicine is clinically applied for a long time, the safety is definite, the toxic and side effects are controllable, the safety evaluation and preparation development risks in the new medicine research and development process are remarkably reduced, and the feasibility and popularization value of industrial application are improved.